Rein Therapeutics (RNTX) Institutional Ownership $1.27 +0.14 (+12.39%) As of 03:59 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Rein Therapeutics (NASDAQ:RNTX)CurrentInstitutional OwnershipPercentage90.89%Number ofInstitutional Buyers(last 12 months)12TotalInstitutional Inflows(last 12 months)$6.97MNumber ofInstitutional Sellers(last 12 months)0 Get RNTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Rein Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data RNTX Institutional Buying and Selling by Quarter Rein Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/14/2025 Cable Car Capital LP420,000$588K0.2%N/A1.822% 8/14/2025 Voss Capital LP1,433,686$2.01M0.1%N/A6.221% 8/13/2025 Northwestern Mutual Wealth Management Co.48,662$68K0.0%N/A0.211% 8/12/2025 BIOS Capital Management LP1,690,751$2.37M3.3%N/A7.335% 8/12/2025 Meridian Wealth Advisors LLC28,486$40K0.0%N/A0.124% 8/11/2025 Senvest Management LLC230,895$323K0.0%N/A1.002% 8/8/2025 Geode Capital Management LLC245,455$344K0.0%N/A1.065% 8/5/2025 Sigma Planning Corp276,777$387K0.0%N/A1.201% 7/31/2025 University of Texas Texas AM Investment Management Co.511,610$716K0.1%N/A2.310% 7/30/2025 Exencial Wealth Advisors LLC30,528$43K0.0%N/A0.138% 7/29/2025 Chicago Partners Investment Group LLC41,242$64K0.0%N/A0.186% 7/24/2025 Blair William & Co. IL23,622$33K0.0%N/A0.107% (Data available from 1/1/2016 forward) RNTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of RNTX shares? During the previous two years, 12 institutional investors and hedge funds held shares of Rein Therapeutics. The most heavily invested institutionals were BIOS Capital Management LP ($2.37M), Voss Capital LP ($2.01M), University of Texas Texas AM Investment Management Co. ($716K), Cable Car Capital LP ($588K), Sigma Planning Corp ($387K), Geode Capital Management LLC ($344K), and Senvest Management LLC ($323K).Learn more on Rein Therapeutics' institutional investors. What percentage of Rein Therapeutics' stock is owned by institutional investors? 90.89% of Rein Therapeutics' stock is owned by institutional investors. Learn more on RNTX's institutional investor holdings. Which institutional investors have been buying Rein Therapeutics' stock? Of the 12 institutional investors that purchased Rein Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BIOS Capital Management LP ($1.69M), Voss Capital LP ($1.43M), University of Texas Texas AM Investment Management Co. ($511.61K), Cable Car Capital LP ($420K), Sigma Planning Corp ($276.78K), Geode Capital Management LLC ($245.46K), and Senvest Management LLC ($230.90K). How much institutional buying is happening at Rein Therapeutics? Institutional investors have bought a total of 4,981,714 shares in the last 24 months. This purchase volume represents approximately $6.97M in transactions. Related Companies ONCY Institutional Ownership HLVX Institutional Ownership TCRX Institutional Ownership MGNX Institutional Ownership SKYE Institutional Ownership ATOS Institutional Ownership BMEA Institutional Ownership ANEB Institutional Ownership OKYO Institutional Ownership XBIT Institutional Ownership This page (NASDAQ:RNTX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rein Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rein Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access